Targeted therapy of Cervix Uteri Cancer

Cervical Cancer (CC) remains one of the most common malignancies affecting women globally. Persistent infection with high-risk types of Human Papillomavirus (HPV) is recognized as the primary cause, as it drives the transformation of normal cervical cells into malignant tumors. Despite advances in disease prevention through HPV vaccines and screening methods, therapeutic options, particularly for advanced stages, are limited. Targeted therapies offer hope by specifically attacking cancer cells while minimizing damage to healthy tissue. Recent research has explored the molecular pathways involved in CC, particularly those activated by HPV early proteins, such as E۶ and E۷, which inhibit tumor suppressor genes like p۵۳ and Rb, leading to uncontrolled cell proliferation. Targeted therapies under investigation include immune checkpoint inhibitors, monoclonal antibodies, and small molecule inhibitors. Additionally, combination therapies, including radiotherapy, chemotherapy, and immune-based treatments, are being evaluated for improved outcomes. Targeted therapies show promise in both clinical and preclinical settings. Data indicate that for certain patients, survival outcomes improved with the use of immunotherapies targeting PD-۱/PD-L۱, particularly when combined with antiangiogenic agents. Moreover, molecular inhibitors targeting key signaling pathways, such as PI۳K/AKT/mTOR, have demonstrated potential in slowing tumor progression. However, challenges such as drug resistance, tumor heterogeneity, and variability in patient response remain significant barriers to treatment success. Targeted therapies are emerging as a promising focus in CC treatment .It is very important to continue the research on the molecular mechanisms of HPV and to develop targeted treatments tailored to the individual characteristics of the patient. While initial results are encouraging, more research is needed to overcome obstacles such as drug resistance and the complex molecular landscape of the disease. Future studies should prioritize personalized treatment strategies that combine novel therapies with established methods to improve patient outcomes. Integrating these approaches holds the promise of increasing the effectiveness of CC treatments and addressing current limitations in care.

کلیدواژه ها:

Cervical Cancer ، HPV ، Targeted therapy ، Immunotherapy ، Molecular pathways